NuGenerex Immuno-Oncology NUGX Stock
NuGenerex Immuno-Oncology Price Chart
NuGenerex Immuno-Oncology NUGX Financial and Trading Overview
| NuGenerex Immuno-Oncology stock price | 0.0001 USD |
| Previous Close | 0.0001 USD |
| Open | 0.0001 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0001 - 0.0001 USD |
| 52 Week Range | 1.0E-5 - 0.3 USD |
| Volume | 1 USD |
| Avg. Volume | 122 USD |
| Market Cap | 10.03K USD |
| Beta (5Y Monthly) | 142.69296 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NUGX Valuation Measures
| Enterprise Value | 1.63M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
NuGenerex Immuno-Oncology Stock Price History
| Beta (5Y Monthly) | 142.69296 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 19.24% |
| 52 Week High | 0.3 USD |
| 52 Week Low | 1.0E-5 USD |
| 50-Day Moving Average | 0.0091718 USD |
| 200-Day Moving Average | 0.0023396 USD |
NUGX Share Statistics
| Avg. Volume (3 month) | 122 USD |
| Avg. Daily Volume (10-Days) | 100 USD |
| Shares Outstanding | 100.3M |
| Float | 36.71M |
| Short Ratio | N/A |
| % Held by Insiders | 66.95% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | July 31, 2020 |
| Most Recent Quarter (mrq) | April 30, 2021 |
| Next Fiscal Year End | July 31, 2021 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -128.78% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -6285032 USD |
| Diluted EPS (ttm) | -0.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | 1.32M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.375 |
| Book Value Per Share (mrq) | -0.088 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -129 USD |
| Levered Free Cash Flow (ttm) | -757681 USD |
Profile of NuGenerex Immuno-Oncology
| Country | United States |
| State | FL |
| City | Miramar |
| Address | 10102 USA Today Way |
| ZIP | 33025 |
| Phone | 416 364 2551 |
| Website | https://www.generex.com/nugenerex-family-of-companies |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 6 |
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.
Q&A For NuGenerex Immuno-Oncology Stock
What is a current NUGX stock price?
NuGenerex Immuno-Oncology NUGX stock price today per share is 0.0001 USD.
How to purchase NuGenerex Immuno-Oncology stock?
You can buy NUGX shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NuGenerex Immuno-Oncology?
The stock symbol or ticker of NuGenerex Immuno-Oncology is NUGX.
Which industry does the NuGenerex Immuno-Oncology company belong to?
The NuGenerex Immuno-Oncology industry is Biotechnology.
How many shares does NuGenerex Immuno-Oncology have in circulation?
The max supply of NuGenerex Immuno-Oncology shares is 100.3M.
What is NuGenerex Immuno-Oncology Price to Earnings Ratio (PE Ratio)?
NuGenerex Immuno-Oncology PE Ratio is 0.00000000 now.
What was NuGenerex Immuno-Oncology earnings per share over the trailing 12 months (TTM)?
NuGenerex Immuno-Oncology EPS is 0 USD over the trailing 12 months.
Which sector does the NuGenerex Immuno-Oncology company belong to?
The NuGenerex Immuno-Oncology sector is Healthcare.